Q2 2025 Earnings Call August 6, 2025 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forwa ...

Market Opportunity & Financial Performance - The quantum computing and networking market is projected to create up to $880 billion in economic value by 2040[8] - IonQ anticipates FY25 revenue between $82 million and $100 million[12] - The company's cash, cash equivalents, and investments balance was $697 million as of March 31, 2025[12] Technology & Roadmap - IonQ is targeting 2 million qubits and 80,000 logical qubits by 2030[10] - The company plans to release a 100-qubit system in 2025[10] - IonQ's error correction overhead is exceedingly low at 13:1[10] Expansion & Acquisitions - IonQ has been expanding its global footprint across 5 countries[10] - The company intends to acquire Oxford Ionics, with the agreement signed in June 2025[12] - IonQ acquired a majority stake in ID Quantique in April 2025[14] Applications & Partnerships - Quantum machine learning applications are expected to impact most industries[9] - Ansys simulation times improved by up to 12% using IonQ's quantum solution[58] - AstraZeneca simulations achieved 20x faster time-to-solution using IonQ's quantum solution[59]

Oncology Programs - Vir Biotechnology is developing potential best-in-class programs across oncology, targeting solid tumors such as HER2, PSMA, and EGFR [12] - VIR-5818 (HER2) showed a 33% response rate and 100% biomarker response in metastatic colorectal cancer (mCRC) at early doses [57] - VIR-5500 (PSMA) demonstrated 100% PSA decline and 58% PSA50 responses at early doses in prostate cancer [57] - VIR-5818 (HER2) showed a molecular response in 54% of subjects based on ctDNA analysis [91, 94] Hepatitis Delta Program - An estimated 61,000 patients in the U S have active viremic HDV infection [22] - Tobevibart + elebsiran combination therapy showed 41% of participants achieving HDV RNA <Target Not Detected (0 IU/mL) at 24 weeks and 64% at 36 weeks in P2 trial [36] - 90% of participants receiving tobevibart + elebsiran achieved HBsAg <10 IU/mL, compared to only 22% with tobevibart monotherapy Q2W at Week 24 [41] - The ECLIPSE registrational clinical trials for Hepatitis Delta are actively enrolling [48] Financial Status - Vir Biotechnology had approximately $892 million in cash and investments as of June 30, 2025, providing a cash runway into mid-2027 [12, 144] - Total revenues for the three months ended June 30, 2025, were $12 million, a 61% decrease compared to $31 million for the same period in 2024 [142]

Financial Performance - Revenue decreased by 25% to $2975 million for the three months ended June 30, 2025, compared to $3965 million in 2024[17] - Net income decreased by 92% to $56 million for the three months ended June 30, 2025, compared to $707 million in 2024[17] - Adjusted EBITDA decreased by 54% to $536 million for the three months ended June 30, 2025, compared to $1159 million in 2024[17] - For the six months ended June 30, 2025, the company recorded a net loss of $26 million, a 101% change compared to a net income of $2077 million in 2024[21] - Revenue decreased by 34% to $5975 million for the six months ended June 30, 2025, from $9000 million in 2024[21] - Adjusted EBITDA decreased by 71% to $931 million for the six months ended June 30, 2025, compared to $3161 million in 2024[21] Production and Sales - Coal production increased by 6% to 2308 thousand short tons for the three months ended June 30, 2025, compared to 2172 thousand short tons in 2024[17] - Coal sales increased by 6% to 2219 thousand short tons for the three months ended June 30, 2025, compared to 2098 thousand short tons in 2024[17] - Coal production increased by 8% to 4562 thousand short tons for the six months ended June 30, 2025, compared to 4223 thousand short tons in 2024[21] - Coal sales increased by 4% to 4391 thousand short tons for the six months ended June 30, 2025, compared to 4227 thousand short tons in 2024[21] Blue Creek Project - The company achieved commercial sales of 239 thousand short tons of Blue Creek steelmaking coal ahead of schedule[10] - The company invested $518 million in the continued development of Blue Creek, bringing the total project-to-date capital expenditures to $8235 million[12] - The longwall startup at Blue Creek is accelerated to early first quarter of 2026[11]

Q2 2025 Highlights - OmniAb sold and installed xPloration instrument shortly after launch, with strong partner interest[11] - Partner pipeline advancement continued[11] - Deal flow and new partner additions are accelerating[11] - Outlook for 2025 remains on track[11] Partnership and Programs - The company has 100 active partners as of June 30, 2025, with 54% in the US, 25% in Europe, 20% in Asia, and 1% in the Middle East[12, 13] - Active programs totaled 381 as of June 30, 2025, a net addition of 18 programs year-to-date[16, 18] - Approximately 99% of active programs have contracted future economics to OmniAb[21] - Antibody Standard Licenses account for 90% of active programs[20] - Total remaining milestones for Antibody Standard Licenses are greater than $3 billion, with an average royalty rate of 3.36%[21] - Post-discovery stage programs have grown by 22% over the last 12 months[24] - There are 32 active clinical programs and approved products as of June 30, 2025[27, 29] Financial Performance - Q2 2025 total revenue was $3.9 million, compared to $7.6 million in Q2 2024[49, 54] - Q2 2025 license and milestone revenue was $1.2 million, down from $3.1 million in Q2 2024[54] - Q2 2025 service revenue was $1.9 million, down from $4.2 million in Q2 2024[54] - Q2 2025 xPloration revenue was $0.6 million[54] - Q2 2025 royalty revenue was $0.1 million, down from $0.3 million in Q2 2024[54] - Q2 2025 net loss was $15.9 million, compared to a net loss of $13.6 million in Q2 2024[54] 2025 Guidance - Revenue is expected to be in the range of $20 million to $25 million[57] - Operating expense is expected to be in the range of $85 million to $90 million[57]

Financial Performance Highlights - Blue Bird's Q3 FY2025 net sales reached $398 million, a $65 million increase compared to Q3 FY2024[20, 25] - The company's Adjusted EBITDA for Q3 FY2025 was $58 million, up $10 million from Q3 FY2024[20, 25] - Adjusted Free Cash Flow for Q3 FY2025 was $52 million, a $56 million increase compared to Q3 FY2024[20, 25] - Blue Bird is raising its full-year FY2025 Adjusted EBITDA guidance to $210 million and expects ~14.5% margin[36, 37] - The company's Q3 Adjusted EBITDA margin was 14.7%, a 20 bps increase compared to Q3 FY2024[21, 27] Business Operations and Backlog - The company sold 2,467 units in Q3 FY2025, an increase of 316 units compared to Q3 FY2024[20, 25] - Blue Bird has a strong backlog of approximately 3,900 units, valued at around $618 million[20, 27] - The company has approximately $174 million in firm orders for electric vehicles (EVs) in its backlog[20] - Alternative power sales accounted for 61% of the sales mix[20] Future Outlook and Capital Allocation - Blue Bird anticipates approximately $1.5 billion in revenue for FY2026, with an Adjusted EBITDA of around $220 million, representing a margin of approximately 14.5%[39] - The company has initiated a new share repurchase program of up to $100 million over two years[32, 34, 52]

Financial Performance - Q2 2025 net product revenue reached $81.5 million, a 164% increase compared to Q2 2024[28,39] - Net product revenues increased by 28% quarter-over-quarter from Q1 2025 to Q2 2025[39,73] - Net loss decreased by 70% from $(52.3) million in Q2 2024 to $(15.9) million in Q2 2025[73] - Cash, cash equivalents, and marketable securities totaled $191.1 million as of June 30, 2025[75] Product & Commercial Updates - ZORYVE portfolio achieved approximately 16,500 weekly total prescriptions on a rolling 4-week basis[40] - Total prescriptions growth was +13% from Q1 2025 to Q2 2025 and +117% compared to Q2 2024[41] - Over 80% of ZORYVE prescriptions are covered by insurance[49] - Launched ZORYVE foam 0.3% for plaque psoriasis of the scalp and body[28] Research & Development - Anticipated approval of ZORYVE cream 0.05% for atopic dermatitis ages 2-5 with target PDUFA October 2025[28,58] - Phase 2 trial initiated for ZORYVE cream 0.05% in ages 3-24 months for atopic dermatitis[58,62]

Business Strategy & Product Development - Veracyte is expanding geographically with IVD products to address patient needs outside the US, with development on track for completion by the end of 2026[20, 21] - NIGHTINGALE enrollment is on track for completion in Q3, targeting 2,400 individuals to demonstrate clinical utility for the nasal swab test for lung cancer risk assessment[22] - The company plans further penetration and share gains, along with launches of MIBC MRD in 1H 2026 and Prosigna LDT2 in mid-2026, with additional MRD platform launches planned[34] Financial Performance (Q2 2025) - GAAP cost of testing revenue reached $32407 thousand[38] - GAAP gross profit was $89769 thousand, with a GAAP gross margin of 690%[38] - GAAP research and development expenses were $16264 thousand[40] - GAAP sales and marketing expenses amounted to $25316 thousand[40] - GAAP general and administrative expenses totaled $32331 thousand[40] - Adjusted EBITDA reached $35776 thousand, representing 275% of revenue[43] - GAAP net loss was $980 thousand, or -08% of revenue[43]

Financial Performance - Total revenue for Q2 2025 reached $264.6 million, a 9% increase year-over-year compared to $242.0 million in Q2 2024[10, 41] - NUPLAZID net sales in Q2 2025 were $168.5 million, up 7% year-over-year from $157.4 million in Q2 2024[10, 41] - DAYBUE net sales in Q2 2025 amounted to $96.1 million, reflecting a 14% increase compared to $84.6 million in Q2 2024[10, 15, 41] - The company's cash and investments balance stands at $762.0 million[41] - The company updates the full year 2025 total revenue guidance to $1.045 to $1.095 billion[44] DAYBUE Updates - 987 unique patients in the U S received DAYBUE in Q2, an increase from 954 in Q1[16] - More than 50% of patients persistency at 12 months and above 45% at 18 months[16] - 70% of active patients have been on therapy for 12 months or longer[16] NUPLAZID Updates - Referrals for NUPLAZID increased by 17% year-over-year[23] - Traffic to NUPLAZID com increased 17 times year-over-year[23] Research and Development - Top-line results from the COMPASS PWS Phase 3 study of ACP-101 are expected in early Q4 2025[11, 35] - The company anticipates filing an NDA for ACP-101 in Q1 2026, assuming positive data from the Phase 3 trial[35] - Phase 2 initiation of ACP-204 in Lewy Body Dementia Psychosis is expected in 3Q25[32]

Financial Performance - Revenue for 2Q 2025 was $145 million, a decrease of 13.6% compared to $168 million in 2Q 2024[10, 24] - Gross margin was 39.2% in 2Q 2025, compared to 42.9% in 2Q 2024[10, 27] - Adjusted EBITDA was $14 million in 2Q 2025, compared to $27 million in 2Q 2024, with a margin of 9.8% versus 15.9%[10, 27] - Adjusted net loss was $1.936 million, compared to an income of $7.269 million in 2Q 2024[27, 42] Revenue Mix & Growth Pillars - Grills accounted for 51% of revenue, consumables 24%, and accessories 25%[12, 13] - Consumables revenue increased by approximately 7% in 2Q 2025[15] Tariff Mitigation & Project Gravity - The company expects to offset approximately 80% of the $60 million unmitigated tariff exposure for Fiscal Year 2025[6, 16] - Project Gravity is expected to drive $30 million of annualized cost savings once fully implemented, with realized savings expected to be up to $13 million in FY 2025[7, 18] Liquidity & Debt - The company had $180 million in liquidity at the end of 2Q 2025, compared to $175 million in 2Q 2024[20] - Net debt was $402 million in 2Q 2025, compared to $409 million in 2Q 2024[20] Fiscal Year 2025 Guidance - Total revenue is projected to be between $540 million and $555 million[29] - Gross margin is expected to be between 40.5% and 41.5%[29] - Adjusted EBITDA is projected to be between $66 million and $73 million[29]